<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829321</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0974-CL-201</org_study_id>
    <secondary_id>2012-005521-73</secondary_id>
    <nct_id>NCT01829321</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis</brief_title>
  <official_title>Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Approximately 45 patients suffering from mild to moderate ulcerative colitis will be
           examined for any side effects (safety and tolerability) that may occur when taking
           GLPG0974 or matching placebo (2:1 ratio) for 28 days.

        -  During the course of the study, patients will also be evaluated for improvement of
           disease activity by different efficacy measures, the amount of GLPG0974 present in the
           blood determined (PK) and the effects of GLPG0974 on selected biomarkers (PD) in the
           blood, colon biopsies and faeces will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Screening up to Follow up (14 days after last dosing)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG0974 in terms of the number of adverse events reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in physical exam measures</measure>
    <time_frame>Screening up to Follow up (14 days after last dosing)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG0974 in terms of the changes in physical exam measures reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs as measured by heart rate, blood pressure and oral temperature</measure>
    <time_frame>Screening up to Follow up (14 days after last dosing)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG0974 in terms of the changes in vital signs as measured by heart rate, blood pressure and oral temperature reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead ECG measures</measure>
    <time_frame>Screening up to Follow up (14 days after last dosing)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG0974 in terms of the changes in 12-lead ECG measures reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood safety lab parameters</measure>
    <time_frame>Screening up to Follow up (14 days after last dosing)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG0974 in terms of changes in blood safety lab parameters reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in urine safety lab parameters</measure>
    <time_frame>Screening up to Follow up (14 days after last dosing)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG0974 in terms of changes in urine safety lab parameters reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in (partial) Mayo clinical disease activity score</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
    <description>To evaluate the efficacy of GLPG0974 in terms of changes in (partial) Mayo clinical disease activity score reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in histopathological clinical activity score in colon biopsies</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>To evaluate the efficacy of GLPG0974 in terms of changes in histopathological clinical activity score (Geboes score) in colon biopsies reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of GLPG0974 in plasma over time after multiple oral doses of GLPG0974</measure>
    <time_frame>Day 8, Day 15 and Day 29</time_frame>
    <description>To evaluate the amount of GLPG0974 in plasma over time after multiple oral doses of GLPG0974 - pharmacokinetics (PK) in ulcerative colitis patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of faecal calprotectin over time after multiple oral doses of GLPG0974</measure>
    <time_frame>Screening up to Day 29</time_frame>
    <description>To evaluate the changes in the levels of calprotectin in faeces over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of C-reactive protein in serum over time after multiple oral doses of GLPG0974</measure>
    <time_frame>Screening up to Day 29</time_frame>
    <description>To evaluate the changes in the levels of C-reactive protein in serum over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of myeloperoxidase (MPO) in colon biopsies over time after multiple oral doses of GLPG0974</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>To evaluate the changes in the levels of MPO in colon biopsies over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of predominant microbiota in faeces over time after multiple oral doses of GLPG0974</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>To evaluate the changes in the levels of predominant microbiota in faeces over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of predominant microbiota in colon biopsies over time after multiple oral doses of GLPG0974</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>To evaluate the changes in the levels of predominant microbiota in colon biopsies over time after multiple oral doses of GLPG0974 - pharmacodynamics (PD) in ulcerative colitis patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>GLPG0974</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule of 200 mg GLPG0974 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0974</intervention_name>
    <description>1 capsule in the morning and 1 capsule in the evening with food during 28 days</description>
    <arm_group_label>GLPG0974</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule in the morning and 1 capsule in the evening with food during 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Men or women between 18 to 75 years of age inclusive, on the day of signing the
             informed consent with a documented history of UC.

          -  Presence of mild-to-moderately active ulcerative colitis as evidenced by clinical
             signs and endoscopy.

          -  Medication: 5-ASA.

          -  Absence of infectious colitis.

        Key Exclusion Criteria:

          -  History of sensitivity to any component of the study drug

          -  Any concurrent illness, condition, disability or clinically significant abnormality
             (including lab tests) that represents a safety risk , may affect the interpretation of
             data, or may prevent the subject to safely complete the assessments

          -  Positive serology for HIV 1 or 2 or hepatitis B or C, or any history of HIV or
             hepatitis.

          -  History of active infections requiring intravenous antibiotics within the past four
             weeks prior to randomization.

          -  History of bowel surgery, or presence or history of intestinal malignancy.

          -  Suspicion of Crohn's disease, indeterminate colitis, microscopic colitis, ischaemic
             colitis or radiation-induced colitis.

          -  History of lower GI bleeding disorder, other than UC.

          -  A history of significant psychological, neurologic, hepatic, renal, endocrine,
             cardiovascular, gastrointestinal (other than UC), pulmonary or metabolic disease.

          -  History of tuberculosis (TB) infection.

          -  Treatment with systemic corticosteroids within 1 week prior to randomization.

          -  Treatment with TNF-α inhibitors or other biologics within 2 months prior to
             randomization.

          -  Treatment with immunosuppressants, initiated or changed within 3 months prior to
             randomization .

          -  Current use of probiotic or prebiotic preparations

          -  Regular daily use of NSAIDs, within 7 days prior to randomization.

          -  Administration of any experimental therapy within 90 days or 5x the half-life.

          -  History of drug or alcohol abuse.

          -  Pregnant or lactating women.

          -  Medical, psychiatric, cognitive, or other conditions that compromise the subject's
             ability to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Vanhoutte, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imelda</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakulní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homolka Hospitál</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Slaný</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajská zdravotní a.s., Masarykova nemocnice v Ústí nad Labem T. Bati a.s.</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajská nemocnice Tomáše Bati - Zlin</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Znojmo</name>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvijas Jūras Medicīnas Centrs</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rīgas slimnīca Bikor Holim</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIA Gremošanas slimību centrs &quot;Gastro&quot;</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná Nemocnica Nitra</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Latvia</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

